Inmune Bio (INMB) Receivables (2021 - 2026)
Inmune Bio (INMB) posted Receivables of $770000.0 for Q1 2026, down 79.64% sequentially from $3.8 million in Q4 2025, and down 45.62% YoY from $1.4 million in Q1 2025.
Inmune Bio (INMB) Receivables (2021 - 2026) Analysis & Trends
Inmune Bio has reported Receivables for 6 years, with the latest figure at $770000.0 in Q1 2026.
- Quarterly Receivables fell 45.62% year-over-year to $770000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $770000.0 (down 45.62% YoY) and the FY2025 annual result came in at $4.5 million, up 420.76% from the prior year.
- Receivables declined to $770000.0 in Q1 2026 per INMB's latest filing, from $3.8 million in the prior quarter.
- Over five years, Receivables peaked at $3.8 million in Q4 2025 and troughed at -$165000.0 in Q2 2022.
- A 5-year average of $1.5 million and a median of $1.4 million in 2025 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2023: Receivables plunged 62.16% in 2022, then soared 751.88% in 2023.
- Over 5 years, Receivables stood at $266000.0 in 2022, then jumped by 751.88% to $2.3 million in 2023, then plunged by 51.54% to $1.1 million in 2024, then jumped by 244.35% to $3.8 million in 2025, then slumped by 79.64% to $770000.0 in 2026.
- According to Business Quant data, Receivables over the past three periods registered $770000.0, $3.8 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | 4.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.77 Mn |
| Mar 31, 2026 | 770,000.00 |
| Dec 31, 2025 | 3.78 Mn |
| Sep 30, 2025 | 2.46 Mn |
| Jun 30, 2025 | 2.16 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 3.73 Mn |
| Dec 31, 2023 | 2.27 Mn |
| Dec 31, 2022 | 266,000.00 |
| Sep 30, 2022 | 80,000.00 |
| Jun 30, 2022 | -165,000.00 |
| Mar 31, 2022 | 108,000.00 |
| Dec 31, 2021 | 703,000.00 |